In August, Melissa Hunt participated in a trial against Meta, the parent company of Instagram, regarding allegations that the platform was designed with addictive features that could harm young users' mental health. Hunt, who is the Associate Director of Clinical Training in the Department of Psychology, provided testimony that contributed to Meta's decision to agree to a settlement of up to $17.1 billion. This settlement resolves not only the case in Tennessee but also a coordinated effort involving 47 states.
Read More
Hunt's involvement stemmed from a significant study she published in 2018, which demonstrated a causal relationship between reduced social media use and improvements in mental health for young adults. This research involved 143 Penn undergraduates who limited their social media usage to a total of 30 minutes a day across platforms such as Facebook, Snapchat, and Instagram. Unlike previous studies relying on self-reported data, Hunt's team tracked actual usage through iPhone monitors. The findings indicated that participants with mild to moderate depression experienced noticeable reductions in their symptoms after cutting back on social media.
Hunt was initially hesitant to testify due to concerns about personal repercussions. However, upon reviewing Meta’s internal documents, which revealed the company's awareness of the potential psychological harms associated with its products, she felt compelled to act. On the witness stand, she articulated findings from Meta's own data, demonstrating that certain product features contributed to increased usage, which in turn led to issues such as depression and anxiety among teenagers.
Although the case did not go to jury deliberation due to the settlement, Hunt was informed that her testimony made a significant impact in the courtroom. The settlement includes measures aimed at protecting minors on Meta's platforms, such as enhanced age verification, expanded parental controls, daily usage limits, and restrictions on beauty filters for underage users.
After the trial, Hunt returned her focus to researching chronic gastrointestinal disorders, while reflecting on her role in holding Meta accountable, stating, "I believe that my participation in this trial will probably end up being one of the most consequential things I do in my career."